Analysts to home in on expenses in Genmab's Wednesday fiscal report

Analysts are awaiting Genmab's fiscal report with anticipation, not due to the sales figures for Darzalex and Kesimpta, but because of expenses.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Analysts will be homing in on listed expenses when Genmab publishes its fiscal report for the first three months of the year on Wednesday afternoon after the stock exchange closes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading